The U.S. House of Representatives may vote as early as tomorrow on a Continuing Resolution (CR) that includes a swath of cuts across the federal budget including a 5+% cut for NIH. Such a cut would have devastating consequences for not only research generally and the U.S. economy, but also specifically for stem cell research. […]

Overall, not focusing just on ES cell research, who is the largest funding agency in the world for stem cell research? If you think about CIRM, funding stem cell grants just in California, versus NIH funding stem cell research across the country, who might you imagine would have provided more funding? I would have thought

In it’s first five years in existence, CIRM has awarded almost $1.2 billion for stem cell research in the state of California in the form of just over 400 grants. To give you some perspective on that amount of research funding, let’s compare this CIRM funding to NIH funding for stem cell research across the

Part of the Republican’s so-called “Pledge to America” was to cut $100 billion from the federal budget. Even though fiscal year 2011 is already almost half over, Republicans driven by Tea Party Mad Hatters have proposed to cut $100 billion from the budget for this year, increasing their proposed cuts of many programs including deeper

Everyone has been understandably stressed about how the ongoing federal legislative process might effect funding for research including stem cell research. Particularly worrisome was the proposal from the new Republican-controlled House of Representatives to cut $100 billion from the budget. Today brought news (reported at one of my favorite blogs, The Great Beyond) that in

What’s going on these days with biotech companies working on stem cell-based products? Geron’s and Advanced Cell Technology (ACT)’s FDA-approved trials presumably continue. As expected, no news yet. It’s too soon. Two important questions regarding both these companies are (1) did they apply for CIRM funding and (2) if so, how did the review process

It’s been more than 4 years since Shinya Yamanaka published the remarkable finding that his lab could transform or “reprogram” regular cells called fibroblasts into a very unique state that was quite similar to that of embryonic stem cells (ESC).  Yamanaka called these new cells “iPS cells” for induced pluripotent stem cells. Since that time,

My post yesterday on the problems with the current system of stem cell funding generated a lot of interest from readers– more than a dozen left comments. Many of the comments were insightful even if readers disagreed on certain points. David Jensen also posted on an interesting piece on this issue in response to our